BioArctic AB (publ) Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

As you might know, BioArctic AB (publ) (STO:BIOA B) recently reported its quarterly numbers. Revenues of kr248m beat expectations by 9.2%. Unfortunately statutory earnings per share (EPS) fell well short of the mark, turning in a loss of kr0.13 compared to previous analyst expectations of a profit. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year.

Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.

Taking into account the latest results, the consensus forecast from BioArctic's dual analysts is for revenues of kr1.35b in 2026. This reflects a huge 35% improvement in revenue compared to the last 12 months. Per-share earnings are expected to bounce 321% to kr5.01. In the lead-up to this report, the analysts had been modelling revenues of kr1.36b and earnings per share (EPS) of kr3.84 in 2026. Although the revenue estimates have not really changed, we can see there's been a sizeable expansion in earnings per share expectations, suggesting that the analysts have become more bullish after the latest result.

See our latest analysis for BioArctic

The consensus price target was unchanged at kr318, implying that the improved earnings outlook is not expected to have a long term impact on value creation for shareholders.

Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. The analysts are definitely expecting BioArctic's growth to accelerate, with the forecast 81% annualised growth to the end of 2026 ranking favourably alongside historical growth of 52% per annum over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 16% per year. Factoring in the forecast acceleration in revenue, it's pretty clear that BioArctic is expected to grow much faster than its industry.

The Bottom Line

The most important thing here is that the analysts upgraded their earnings per share estimates, suggesting that there has been a clear increase in optimism towards BioArctic following these results. Happily, there were no major changes to revenue forecasts, with the business still expected to grow faster than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.

Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. We have analyst estimates for BioArctic going out as far as 2028, and you can see them free on our platform here.

We don't want to rain on the parade too much, but we did also find 1 warning sign for BioArctic that you need to be mindful of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.